Journal List > Allergy Asthma Respir Dis > v.4(3) > 1059186

TOOLS
Lee, Kang, Jung, Jang, Lee, Ahn, Min, and Korean Academy of Asthma, Allergy and Clinical Immunology Anaphylaxis Work Group: ERRATUM: Correction of explanation for footnote in Table 3. Clinical experience in managing patients with hereditary angioedema in Korea: questionnaire survey and a literature review
Erratum

Allergy, Asthma & Respiratory Disease 2016; 4(3): 230.

Published online: 31 May 2016

DOI: https://doi.org/10.4168/aard.2016.4.3.230

ERRATUM: Correction of explanation for footnote in Table 3. Clinical experience in managing patients with hereditary angioedema in Korea: questionnaire survey and a literature review

Suh-Young Lee1, Hye-Ryun Kang1, Jae Woo Jung2, Gwang Cheon Jang3, Soo Young Lee4, Youngmin Ahn5, Kyung-Up Min1; Korean Academy of Asthma, Allergy and Clinical Immunology Anaphylaxis Work Group

1Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.

2Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.

3Department of Pediatrics, National Health Insurance Corporation Ilsan Hospital, Goyang, Korea.

4Department of Pediatrics and Adolescent Medicine, Ajou University School of Medicine, Suwon, Korea.

5Department of Pediatrics, Eulji University School of Medicine, Daejeon, Korea.

© 2016 The Korean Academy of Pediatric Allergy and Respiratory Disease; The Korean Academy of Asthma, Allergy and Clinical Immunology

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/).
Allergy Asthma Respir Dis 2014;2(4):277-284 http://dx.doi.org/10.4168/aard.2014.2.4.277
*Only Cinryze is approved for maintenance treatment by Food and Drug Administration. †Bradykinin B2 receptor antagonist. ‡Kallikrein inhibitor.
TOOLS
Similar articles